Потенциальное влияние некоторых факторов на течение псориаза у детей

Псориаз является вторым наиболее частым заболеванием кожи после атопического дерматита в детском возрасте. Существуют факторы, влияющие как на манифестацию, так и на обострение данного воспалительного кожного процесса. Ведущее значение в патогенезе псориаза в настоящее время отводится роли ключевых цитокинов. Тем не менее, триггерами псориаза также могут быть инфекционные заболевания.

В настоящее время подход к лечению псориаза у детей пересматривается в связи с появлением новых знаний об особенностях клинических проявлений и влиянии многочисленных коморбидных состояний на течение данной патологии. Оценка факторов риска, признаков и симптомов потенциальных сопутствующих заболеваний является важным компонентом ведения пациентов для построения прогностической модели прогрессирования основного заболевания и развития обострений, в том числе на фоне сопутствующих воспалительных процессов.

1. Menter A, Cordoro KM, Davis DMR, et al. Joint American Academy of Dermatology-National Psoriasis Foundation guidelines of care for the management and treatment of psoriasis in pediatric patients. J Am Acad Dermatol. 2020;82(1):161–201. https://doi.org/10.1016/j.jaad.2019.08.049

2. Tkach VY, Voloshynovych MS, Girnyk GY, Kozak NV. Clinical features and the course of psoriasis in children. Dermatology Review. 2020;107(5):476–480. https://doi.org/10.5114/dr.2020.101677

3. Pinson R, Sotoodian B, Fiorillo L. Psoriasis in children. Psoriasis (Auckl). 2016;6:121–129. https://doi.org/10.2147/PTT.S87650

4. Paller AS, Singh R, Cloutier M, et al. Prevalence of psoriasis in children and adolescents in the United States: A claims-based analysis. J Drugs Dermatol. 2018;17(2):187–194.

5. Schön MP, Boehncke WH. Psoriasis. N Engl J Med. 2005;352(18):1899–1912. https://doi.org/10.1056/NEJMra041320

6. Tangtatco JAA, Lara-Corrales I. Update in the management of pediatric psoriasis. Curr Opin Pediatr. 2017;29(4):434–442. https://doi.org/10.1097/MOP.0000000000000517

7. Dand N, Mahil SK, Capon F, et al. Psoriasis and Genetics. Acta Derm Venereol. 2020;100(3):adv00030. https://doi.org/10.2340/00015555-3384

8. Trembath RC, Clough RL, Rosbotham JL, et al. Identification of a major susceptibility locus on chromosome 6p and evidence for further disease loci revealed by a two stage genome-wide search in psoriasis. Hum Mol Genet. 1997;6(5):813–820. https://doi.org/10.1093/hmg/6.5.813

9. Strange A, Capon F, Spencer CC, et al. A genome-wide association study identifies new psoriasis susceptibility loci and an interaction between HLAC and ERAP1. Nat Genet. 2010;42(11):985–990. https://doi.org/10.1038/ng.694

10. Berki DM, Liu L, Choon SE, et al. Activating CARD14 Mutations Are Associated with Generalized Pustular Psoriasis but Rarely Account for Familial Recurrence in Psoriasis Vulgaris. J Invest Dermatol. 2015;135(12):2964–2970. https://doi.org/10.1038/jid.2015.288

11. Liang Y, Sarkar MK, Tsoi LC, Gudjonsson JE. Psoriasis: A mixed autoimmune and autoinflammatory disease. Curr Opin Immunol. 2017;49:1–8. https://doi.org/10.1016/j.coi.2017.07.007

12. Kamata M, Tada Y. Dendritic Cells and Macrophages in the Pathogenesis of Psoriasis. Front Immunol. 2022;13:941071. https://doi.org/10.3389/fimmu.2022.941071

13. Campanati A, Ganzetti G, Di Sario A, et al. The effect of etanercept on hepatic fibrosis risk in patients with non-alcoholic fatty liver disease, metabolic syndrome, and psoriasis. J Gastroenterol. 2013;48(7):839–846. https://doi.org/10.1007/s00535-012-0678-9

14. Bronckers IMGJ, Paller AS, Van Geel MJ, et al. Psoriasis in Children and Adolescents: Diagnosis, Management and Comorbidities. Pediatr Drugs. 2015;17(5):373–384. https://doi.org/10.1007/s40272-015-0137-1

15. Becker L, Tom WL, Eshagh K, et al. Excess adiposity preceding pediatric psoriasis. JAMA Dermatol. 2014;150(5):573–574. https://doi.org/10.1001/jamadermatol.2014.324

16. Амбарчян Э.Т., Намазова-Баранова Л.С., Мурашкин Н.Н. и др. Лептин и эпикардиальный жир: новые маркеры псориазау детей? Проспективное одномоментное исследование // Педиатрическая фармакология. — 2022. — Т. 19. — № 3. — С. 242–249. — https://doi.org/10.15690/pf.v19i3.2481

17. Намазова-Баранова Л.С., Амбарчян Э.Т., Иванчиков В.В. и др. Изменение толщины эпикардиальной жировой ткани у детей с псориазом на фоне биологической терапии: проспективное когортное исследование // Вопросы современной педиатрии. — 2023. — Т. 22. — № 5. — С. 406–414. — https://doi.org/10.15690/vsp.v22i5.2641

18. Thomas J, Parimalam K. Treating pediatric plaque psoriasis: Challenges and solutions. Pediatric Health Med Ther. 2016;7:25–28. https://doi.org/10.2147/PHMT.S75834

19. Kimball AB, Wu EQ, Guerin A, et al. Risks of developing psychiatric disorders in pediatric patients with psoriasis. J Am Acad Dermatol. 2012;67(4):651–657. https://doi.org/10.1016/j.jaad.2011.11.948

20. Brihan I, Ianoși SL, Boda D, et al. Implications of self-esteem in the quality of life in patients with psoriasis. Exp Ther Med. 2020;20(2):202. https://doi.org/10.3892/etm.2020.9332

21. van de Kerkhof PCM, Nestlé FO. Psoriasis. In: Dermatology. Bolognia JL, Schaffer JV, Cerroni L, eds. 4th edn. Philadelphia, PA: Elsevier; 2018. pp. 138–160.

22. Tollefson MM. Diagnosis and management of Psoriasis in children. Pediatr Clin North Am. 2014;61(2):261–277. https://doi.org/10.1016/j.pcl.2013.11.003

23. Хайрутдинов В.Р. Генетический паспорт больного псориазом // Вестник дерматологии и венерологии. — 2011. — № 4. — С. 14–19.

24. Cunningham MW. Pathogenesis of group A streptococcal infections. Clin Microbiol Rev. 2000;13(3):470–511. https://doi.org/10.1128/cmr.13.3.470-511.2000

25. Davison SC, Ballsdon A, Allen MH, et al. Early migration of cutaneous lymphocyte-associated antigen (CLA) positive T cells into evolving psoriatic plaques. Exp Dermatol. 2001;10(4): 280–285. https://doi.org/10.1034/j.1600-0625.2001.100408.x

26. Allen HB, Jadeja S, Allawh RM, Goyal K. Psoriasis, chronic tonsillitis, and biofilms: Tonsillar pathologic findings supporting a microbial hypothesis. Ear Nose Throat J. 2018;97(3):79–82. https://doi.org/10.1177/014556131809700322

27. Watanabe R, Gehad A, Yang C, et al. Human skin is protected by four functionally and phenotypically discrete populations of resident and recirculating memory T cells. Sci Transl Med. 2015;7(279):279ra39. https://doi.org/10.1126/scitranslmed.3010302

28. De Jesús-Gil C, Ruiz-Romeu E, Ferran M, et al. CLA(+) T Cell Response to Microbes in Psoriasis. Front Immunol. 2018;9:1488. https://doi.org/10.3389/fimmu.2018.01488

29. Thorleifsdottir RH, Sigurdardottir SL, Sigurgeirsson B, et al. Improvement of psoriasis after tonsillectomy is associated with a decrease in the frequency of circulating T cells that recognize streptococcal determinants and homologous skin determinants. J Immunol. 2012;188(10):5160–5165. https://doi.org/10.4049/jimmunol.1102834

30. Rachakonda TD, Dhillon JS, Florek AG, Armstrong AW. Effect of tonsillectomy on psoriasis: A systematic review. J Am Acad Dermatol. 2015;72(2):261–275. https://doi.org/10.1016/j.jaad.2014.10.013

31. Thorleifsdottir RH, Sigurdardottir SL, Sigurgeirsson B, et al. Patient-reported outcomes and clinical response in patients with moderate-to-severe plaque psoriasis treated with tonsillectomy: A randomized controlled trial. Acta Derm Venereol. 2017;97(3):340–345. https://doi.org/10.2340/00015555-2562

32. Ungprasert P, Wijarnpreecha K, Wetter DA. Periodontitis and risk of psoriasis: A systematic review and meta-analysis. J Eur Acad Dermatol Venereol. 2017;31(5):857–862. https://doi.org/10.1111/jdv.14051

33. Abdullah SN, Farmer EA, Spargo L, et al. Porphyromonas gingivalis peptidylarginine deiminase substrate specificity. Anaerobe. 2013;23:102–108. https://doi.org/10.1016/j.anaer-obe.2013.07.001

34. Zhang X, Gu H, Xie S, Su Y. Periodontitis in patients with psoriasis: A systematic review and meta-analysis. Oral Dis. 2022;28(1):33–43. https://doi.org/10.1111/odi.13617

35. Taheri Sarvtin M, Shokohi T, Hajheydari Z. Evaluation of candidal colonization and specific humoral responses against Candida albicans in patients with psoriasis. Int J Dermatol. 2014;53(12):e555– e560. https://doi.org/10.1111/ijd.12562

36. Gaitanis G, Velegraki A, Mayser P, Bassukas ID. Skin diseases associated with Malassezia yeasts: facts and controversies. Clin Dermatol. 2013;31(4):455–463. https://doi.org/10.1016/j.clindermatol.2013.01.012

37. Liu X, Cai Q, Yang H, et al. Distribution of Malassezia species on the skin of patients with psoriasis. J Mycol Med. 2021;31(2):101111. https://doi.org/10.1016/j.mycmed.2021.101111

38. Chang CH, Stein SL. Malassezia-associated skin diseases in the pediatric population. Pediatr Dermatol. 2024. https://doi.org/10.1111/pde.15603

39. Gomez-Moyano E, Crespo-Erchiga V, Martinez-Pilar L, et al. Do Malassezia species play a role in exacerbation of scalp psoriasis? J Mycol Med. 2014;24(2):87–92. https://doi.org/10.1016/j.mycmed.2013.10.007

40. Honnavar P, Chakrabarti A, Dogra S, et al. Phenotypic and molecular characterization of Malassezia japonica isolated from psoriasis vulgaris patients. J Med Microbiol. 2015;64(Pt 3):232–236. https://doi.org/10.1099/jmm.0.000011

41. Gemmer CM, Deangelis YM, Theelen B, et al. Fast, noninvasive method for molecular detection and differentiation of Malassezia yeast species on human skin and application of the method to dandruff microbiology. J Clin Microbiol. 2002;40(9):3350–3357. https://doi.org/10.1128/JCM.40.9.3350-3357.2002

42. Kanda N, Tani K, Enomoto U, et al. The skin fungus-induced Th1-and Th2-related cytokine, chemokine and prostaglandin E2 production in peripheral blood mononuclear cells from patients with atopic dermatitis and psoriasis vulgaris. Clin Exp Allergy. 2002;32(8):1243–1250. https://doi.org/10.1046/j.1365-2745.2002.01459.x

43. Valli JL, Williamson A, Sharif S, et al. In vitro cytokine responses of peripheral blood mononuclear cells from healthy dogs to distemper virus, Malassezia and Toxocara. Vet Immunol Immunopathol. 2010;134(3-4):218–229. https://doi.org/10.1016/j.261vetimm.2009.09.023

44. Baroni A, Paoletti I, Ruocco E, et al. Possible role of Malassezia furfur in psoriasis: modulation of TGF-beta1, integrin, and HSP70 expression in human keratinocytes and in the skin of psoriasisaffected patients. J Cutan Pathol. 2004;31(1):35–42. https://doi.org/10.1046/j.0303-6987.2004.0135.x

45. Farr PM, Krause LB, Marks JM, Shuster S. Response of scalp psoriasis to oral ketoconazole. Lancet. 1985;2(8461):921–922. https://doi.org/10.1016/S0140-6736(85)90853-0

46. Beck KM, Yang EJ, Sanchez IM, Liao W. Treatment of Genital Psoriasis: A Systematic Review. Dermatol Ther (Heidelb). 2018;8(4):509–525. https://doi.org/10.1007/s13555-018-0257-y

47. Fang H, Hou Y, Zhuang H, Wang C. The effects of Malassezia in the activation of Interleukin (IL)-23/IL-17 axis in Psoriasis. New Microbiol. 2022;45(2):130–137.

48. Pellicano R, Ribaldone DG, Fagoonee S, et al. A 2016 panorama of Helicobacter pylori infection: key messages for clinicians. Panminerva Med. 2016 58(4):304–137.

49. Al-Mendalawi M. Screening of Helicobacter pylori in patients with alopecia areata. Menoufia Med J. 2019;32(2):748. https://doi.org/10.4103/mmj.mmj_826_17

50. Magen E, Delgado JS. Helicobacter pylori and skin autoimmune diseases. World J Gastroenterol. 2014;20(6):1510–1516. https://doi.org/10.3748/wjg.v20.i6.1510

51. Reid C, Griffiths CEM. Psoriasis and Treatment: Past, Present and Future Aspects. Acta Derm Venereol. 2020;100(3):adv00032. https://doi.org/10.2340/00015555-3386

52. Nogueira M, Puig L, Torres T. JAK Inhibitors for Treatment of Psoriasis: Focus on Selective TYK2 Inhibitors. Drugs. 2020;80(4):341–352. https://doi.org/10.1007/s40265-020-01261-8

53. Jiang Y, Chen Y, Yu Q, Shi Y. Biologic and Small-Molecule Therapies for Moderate-to-Severe Psoriasis: Focus on Psoriasis Comorbidities. BioDrugs. 2023;37(1):35–55. https://doi.org/10.1007/s40259-022-00569-z